Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Down 11.5% in February

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 105,100 shares, a decline of 11.5% from the January 31st total of 118,800 shares. Based on an average trading volume of 193,700 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Investors Weigh In On Enlivex Therapeutics

Several hedge funds have recently made changes to their positions in ENLV. Two Sigma Securities LLC purchased a new stake in shares of Enlivex Therapeutics in the 4th quarter worth $26,000. Renaissance Technologies LLC raised its position in shares of Enlivex Therapeutics by 112.6% in the 4th quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock worth $186,000 after acquiring an additional 84,203 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of Enlivex Therapeutics in the 4th quarter worth $742,000. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

Enlivex Therapeutics Trading Up 1.8 %

Shares of ENLV stock opened at $1.15 on Friday. Enlivex Therapeutics has a twelve month low of $0.81 and a twelve month high of $4.59. The stock has a market capitalization of $24.62 million, a price-to-earnings ratio of -1.17 and a beta of 1.11. The stock has a fifty day simple moving average of $1.12 and a two-hundred day simple moving average of $1.25.

Wall Street Analyst Weigh In

Separately, D. Boral Capital reiterated a “buy” rating and issued a $13.00 target price on shares of Enlivex Therapeutics in a report on Monday.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.